JP2024537864A5 - - Google Patents
Info
- Publication number
- JP2024537864A5 JP2024537864A5 JP2024520855A JP2024520855A JP2024537864A5 JP 2024537864 A5 JP2024537864 A5 JP 2024537864A5 JP 2024520855 A JP2024520855 A JP 2024520855A JP 2024520855 A JP2024520855 A JP 2024520855A JP 2024537864 A5 JP2024537864 A5 JP 2024537864A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- seq
- specifically
- weeks
- risdiplam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21201211 | 2021-10-06 | ||
| EP21201211.6 | 2021-10-06 | ||
| PCT/EP2022/077494 WO2023057404A1 (en) | 2021-10-06 | 2022-10-04 | Novel combined administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537864A JP2024537864A (ja) | 2024-10-16 |
| JP2024537864A5 true JP2024537864A5 (enExample) | 2025-11-11 |
Family
ID=78085538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520855A Pending JP2024537864A (ja) | 2021-10-06 | 2022-10-04 | 新規併用投与 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240358704A1 (enExample) |
| EP (1) | EP4426306A1 (enExample) |
| JP (1) | JP2024537864A (enExample) |
| CN (1) | CN118055767A (enExample) |
| WO (1) | WO2023057404A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025534681A (ja) | 2022-10-14 | 2025-10-17 | ジェネンテック， インコーポレイテッド | 脊髄性筋萎縮症の治療方法 |
| AU2024365291A1 (en) * | 2023-10-27 | 2026-02-19 | F. Hoffmann-La Roche Ag | New composition for treating spinal muscular atrophy |
| CN118045206B (zh) * | 2024-04-12 | 2024-07-05 | 四川至善唯新生物科技有限公司 | 一种治疗脊髓型肌肉萎缩的药物组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AU2015261046C1 (en) | 2014-05-15 | 2019-07-25 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| AU2016353961B2 (en) | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| EA201891420A1 (ru) | 2015-12-18 | 2019-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения |
| CN115814077A (zh) * | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| PL4218804T3 (pl) * | 2016-06-13 | 2026-05-25 | Scholar Rock, Inc. | Stosowanie inhibitorów miostatyny i terapii skojarzonych |
| CN120554386A (zh) | 2018-10-19 | 2025-08-29 | 豪夫迈·罗氏有限公司 | 新型吡啶并[1,2-a]嘧啶-4-酮衍生物、其制剂及制备方法 |
| EP4013387A4 (en) * | 2019-08-15 | 2023-09-27 | Biogen MA Inc. | COMBINATION THERAPY FOR SPINAL MUSCLE ATROPHY |
-
2022
- 2022-10-04 EP EP22802517.7A patent/EP4426306A1/en active Pending
- 2022-10-04 JP JP2024520855A patent/JP2024537864A/ja active Pending
- 2022-10-04 CN CN202280067699.6A patent/CN118055767A/zh active Pending
- 2022-10-04 WO PCT/EP2022/077494 patent/WO2023057404A1/en not_active Ceased
-
2024
- 2024-04-05 US US18/627,727 patent/US20240358704A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016177A5 (enExample) | ||
| JP2019534003A5 (enExample) | ||
| CN103338772A (zh) | 用于预防或治疗青光眼的药物疗法 | |
| JP2022512704A5 (enExample) | ||
| JP2022536469A5 (enExample) | ||
| US20220323437A1 (en) | Methods for treating pulmonary arterial hypertension | |
| EP1237559B1 (en) | Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran | |
| JP2022550919A5 (enExample) | ||
| JP2024540226A5 (enExample) | ||
| EP4076511A1 (en) | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies | |
| JP2024518536A5 (enExample) | ||
| JP2021511043A5 (enExample) | ||
| JP2024543885A5 (enExample) | ||
| JP2022531205A5 (enExample) | ||
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2025511167A5 (enExample) | ||
| JP2021523138A5 (enExample) | ||
| JP2023511956A5 (enExample) | ||
| JP2022536669A5 (enExample) | ||
| JP2022514561A5 (enExample) | ||
| JP2023544620A5 (enExample) | ||
| US20230227555A1 (en) | Cd-3 antibodies for the treatment of coronavirus | |
| JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
| CN100496500C (zh) | 含布那唑嗪和前列腺素的青光眼治疗剂 | |
| JP2023506779A5 (enExample) |